Skip to content

The Immunoregulatory Effects of Interleukin-27 in Severe Acute Pancreatitis

The Immunoregulatory Effects of Interleukin-27 in Severe Acute Pancreatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098831
Enrollment
Unknown
Registered
2025-03-13
Start date
2023-10-25
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnosed acute pancreatitis with severe acute pancreatitis

Interventions

Sponsors

The First People's Hospital of Zunyi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who visited the outpatient or inpatient departments of the Third Affiliated Hospital of Zunyi Medical University from October 2023 to September 2024 will be included as the sample source. Healthy individuals undergoing physical examinations during the same period will serve as the control group. The sample collection and experimental protocols have been approved by the Ethics Committee of the Third Affiliated Hospital of Zunyi Medical University. 2. AP Diagnosis Criteria: Persistent upper abdominal pain, serum amylase (AMY) and/or lipase (LPS) levels exceeding three times the upper limit of normal, and abdominal imaging showing changes consistent with acute pancreatitis. Meeting at least two of these three criteria is required. 3. SAP Diagnosis Criteria: In addition to the AP diagnosis criteria, the presence of infected pancreatic (peri-pancreatic) necrosis or persistent (>48 hours) organ dysfunction (based on the modified Marshall scoring system, with any organ score =2 indicating organ dysfunction).

Exclusion criteria

Exclusion criteria: 1. Exclusion Criteria: Pregnancy or lactation; 2. Presence of sepsis; 3. Malignant tumors; 4. Organ transplantation; 5. Chronic viral infections (hepatitis, HIV); 6. Liver cirrhosis; 7. Chronic renal insufficiency; 8. Autoimmune diseases; 9. Use of immunosuppressive drugs within the past 8 weeks.

Design outcomes

Primary

MeasureTime frame
IL-27;

Secondary

MeasureTime frame
IL-27;IL-6;amylase;LPS;C-reactive protein;

Countries

China

Contacts

Public ContactLei Kun

The First People's Hospital of Zunyi

Rekyland@outlook.com+86 851 23110546

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026